Kyorin pact another arrow in Daiichi Sankyo's South American quiver
This article was originally published in Scrip
In another move to build up its business in major emerging markets, Daiichi Sankyo has acquired exclusive development and commercialisation rights in Brazil to Kyorin Pharmaceutical's overactive bladder therapy imidafenacin.
You may also be interested in...
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.
Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.